exokinaseⅡ role in tumor growth and targeting therapyW

doi:10.3760/cma.j.issn.1673422X.2017.03.014

Abstract

Abstract: The energy for tumor cells mainly derives from the aerobic glycolysis, that is, the Warburg effect, which also provides a large amount of precursor substances for the growth of tumor cells. HexokinaseⅡ (HKⅡ), highly expressed in tumor tissue, is the ratelimiting enzyme of glycolysis and closely related to the energy metabolism of tumor. Recent studies have showed that HKⅡ not only mediates Warburg effect, but also promotes tumor proliferation by inhibiting tumor cell apoptosis and regulating autophagy. It has been confirmed that blocking HKⅡ gene expression and inhibiting HKⅡ with small molecule inhibitor can kill tumor cells in many kinds of cancer. Agent targeting HKⅡ may become a new generation of targeted drugs.

Key words: Hexokinase, Neoplasms, Cell proliferation; Target therapy

Wang Haohua, Chen Xiuxing, Guo Guifang. exokinaseⅡ role in tumor growth and targeting therapyW[J]. Journal of International Oncology, 2017, 44(3): 213-216.

References

［1］ Masoud GN, Li W. HIF1alpha pathway: role, regulation and intervention for cancer therapy［J］. Acta pharmaceutica Sinica B, 2015, 5 (5): 378-389. DOI: 10.1016/j.apsb.2015.05.007. ［2］ Gregersen LH, Jacobsen A, Frankel LB, et al. MicroRNA143 downregulates Hexokinase 2 in colon cancer cells［J］. BMC Cancer, 2012, 12: 232. DOI: 10.1186/1471240712232. ［3］ Yoshino H, Enokida H, Itesako T, et al. Tumorsuppressive microRNA 143/145 cluster targets hexokinase2 in renal cell carcinoma［J］. Cancer Sci, 2013, 104(12): 1567-1574. DOI: 10.1111/cas.12280. ［4］ Jiang S, Zhang LF, Zhang HW, et al. A novel miR155/miR143 cascade controls glycolysis by regulating hexokinase 2 in breast cancer cells［J］. EMBO J, 2012, 31(8): 1985-1998. DOI: 10.1038/emboj.2012.45. ［5］ Zhang LF, Lou JT, Lu MH, et al. Suppression of miR199a maturation by HuR is crucial for hypoxiainduced glycolytic Switch in hepatocellular carcinoma［J］. EMBO J, 2015, 34(21): 2671-2685. DOI: 10.15252/embj.201591803. ［6］ Li LQ, Yang Y, Chen H, et al. MicroRNA181b inhibits glycolysis in gastric cancer cells via targeting hexokinase 2 gene［J］. Cancer Biomark, 2016, 17(1): 75-81. DOI: 10.3233/CBM160619. ［7］ Wang Y, Yun Y, Wu B, et al. FOXM1 promotes reprogramming of glucose metabolism in epithelial ovarian cancer cells via activation of GLUT1 and HK2 transcription［J］. Oncotarget, 2016, In press. DOI: 10.18632/oncotarget.10103. ［8］ Roberts DJ, Miyamoto S. Hexokinase Ⅱ integrates energy metabolism and cellular protection: akting on mitochondria and TORCing to autophagy［J ］. Cell Death Differ, 2015, 22(2): 248-257. DOI: 10.1038/cdd.2014.173. ［9］ Pantic B, Trevisan E, Citta A, et al. Myotonic dystrophy protein kinase (DMPK) prevents ROSinduced cell death by assembling a hexokinase ⅡSrc complex on the mitochondrial surface［J］. Cell Death Dis, 2013, 4: e858. DOI: 10.1038/cddis.2013.385. ［10］ Roberts DJ, TanSah VP, Ding EY, et al. HexokinaseⅡ positively regulates glucose starvationinduced autophagy through TORC1 inhibition［J ］. Mol Cell, 2014, 53(4): 521-533. DOI: 10.1016/j.molcel.2013.12.019. ［11］ Tan VP, Miyamoto S. HK2/hexokinaseⅡ integrates glycolysis and autophagy to confer cellular protection［J］. Autophagy, 2015, 11(6): 963- 964. DOI: 10.1080/15548627.2015.1042195. ［12］ Kim JE, Ahn BC, Hwang MH, et al. Combined RNA interference of hexokinase Ⅱ and (131)Isodium iodide symporter gene therapy for anaplastic thyroid carcinoma［J］ . J Nucl Med, 2011, 52(11): 1756-1763. DOI: 10.2967/jnumed.111.090266. ［13］ Wolf A, Agnihotri S, Micallef J, et al. Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme［J］. J Exp Med, 2011, 208(2): 313-326. DOI: 10.1084/jem.20101470. ［14］ Patra KC, Wang Q, Bhaskar PT, et al. Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer［J］. Cancer Cell, 2013, 24(2): 213-228. DOI: 10.1016/j.ccr.2013.06.014. ［15］ Gong L, Wei Y, Yu X, et al. 3Bromopyruvic acid, a hexokinase Ⅱ inhibitor, is an effective antitumor agent on the hepatoma cells: in vitro and in vivo findings［J］. Anticancer Agents Med Chem, 2014, 14(5): 771-776. ［16］ Buijs M, Wijlemans JW, Kwak BK, et al. Antiglycolytic therapy combined with an imageguided minimally invasive delivery strategy for the treatment of breast cancer［J］. J Vasc Interv Radiol, 2013, 24(5): 737-743. DOI: 10.1016/j.jvir.2013.01.013. ［17］ Wicks RT, Azadi J, Mangraviti A, et al. Local delivery of cancercell glycolytic inhibitors in highgrade glioma［J］. Neuro Oncol, 2015, 17(1): 70-80. DOI: 10.1093/neuonc/nou143. ［18］ Krasnov GS, Dmitriev AA, Lakunina VA, et al. Targeting VDACbound hexokinase Ⅱ: a promising approach for concomitant anticancer therapy［J ］. Expert Opin Ther Targets, 2013, 17(10): 1221-1233. DOI: 10.1517/14728222.2013.833607. ［19］ Wintzell M, Lfstedt L, Johansson J, et al. Repeated cisplatin treatment can lead to a multiresistant tumor cell population with stem cell features and sensitivity to 3bromopyruvate［J］. Cancer Biol Ther, 2012, 13(14): 1454-1462. DOI: 10.4161/cbt.22007. ［20］ Bean JF, Qiu YY, Yu S, et al. Glycolysis inhibition and its effect in doxorubicin resistance in neuroblastoma［J］. J Pediatr Surg, 2014, 49 (6): 981-984; discussion 984. DOI: 10.1016/j.jpedsurg.2014.01.037. ［21］ GarbutcheonSingh KB, Harper BW, Myers S, et al. Combination studies of Platinum(Ⅱ)based metallointercalators with buthionineS, R sulfoximine, 3bromopyruvate, cisplatin or carboplatin［J］. Metallomics, 2014, 6(1): 126-131. DOI: 10.1039/c3mt00191a. ［22］ Marrache S, Dhar S. The energy blocker inside the power house: mitochondria targeted delivery of 3bromopyruvate［J］. Chem Sci, 2015, 6 (3): 1832-1845. ［23］ Zhang MX, Hua YJ, Wang HY, et al. Longterm prognostic implications and therapeutic target role of hexokinase Ⅱ in patients with nasopharyngeal carcinoma［J］. Oncotarget, 2016, 7(16): 21287-21297. DOI: 10.18632/oncotarget.7116. ［24］ Kennedy CR, Tilkens SB, Guan H, et al. Differential sensitivities of glioblastoma cell lines towards metabolic and signaling pathway inhibitions ［J］. Cancer Lett, 2013, 336(2): 299-306. DOI: 10.1016/j.canlet.2013.03.020. ［25］ Cheong JH, Park ES, Liang J, et al. Dual inhibition of tumor energy pathway by 2deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models［J］. Mol Cancer Ther, 2011, 10(12): 2350-2362. DOI: 10.1158/15357163.MCT110497.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying. Research progress of habitat analysis in radiomics of malignant tumors [J]. Journal of International Oncology, 2024, 51(5): 292-297.